Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of pelabresib (CPI-0610) with or without ruxolitinib in myelofibrosis and pelabresib monotherapy in essential thrombocythemia
NL-OMON52821Phase 2Completed
- Sponsor
- Constellation Pharmaceuticals
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of pelabresib and ruxolitinib, sponsored by Constellation Pharmaceuticals. Started Jun 2019; status: completed.
02
Drugs
pelabresibruxolitinib
Beyond the preview
Go deeper on NL-OMON52821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52821.